Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Realty Income Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.99 (market cap $29.60B), while Realty Income Corp trades at $62.4 (market cap $58.56B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays a 5.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | O | |
|---|---|---|
Market Cap | $29.60B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $67.56 |
52-Week Low | $205.48 | $55.93 |
Enterprise Value | $27.56B | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Realty Income (O) trades at $62.43, up 0.87% with a bearish technical signal despite bullish oscillators. The REIT reported three consecutive quarterly EPS misses but maintains strong fundamentals with 92.56% gross margins and 21.23% net income margin. Recent news highlights a $875 million convertible notes offering and the company's 115th consecutive dividend increase, supporting its monthly dividend reputation. Revenue growth continues from $5.3B in 2024 to $5.7B in 2025, though debt-to-asset ratio has risen to 39.93%.
The stock presents a mixed outlook with analyst consensus at Buy (41%) and $67.29 price target offering 7.8% upside. Key opportunities include reliable dividends and portfolio expansion into data centers, while risks involve rising leverage and interest rate sensitivity. Technical resistance at $62-63 levels may cap near-term gains despite oversold RSI conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
